An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.
VERDICT
The label
Markup
read at $11.80
COMPASS Pathways plc holds its Markup at $11.80.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-08-04
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 5 days
Price
$11.80
Valuation
N/A trailing · -8.81 forward price to earnings
Values screen
PASS· score 95.2
Beta
2.53
OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads FAIR VALUE — it trades at roughly a 74% discount to our $20.50 fair value.
Read at
$11.80
N/A P/E · -8.81 fwd
Our fair value
$20.50
74% discount
Analyst target (avg)
$20.50
+74% to current
Target low $13.00Analyst target rangeTarget high $70.00
▲ current $11.80 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$11.80
you are here
Conservative
$13.00
+10%
Analyst avg
$20.50
+74%
Our fair value
$20.50
+74%
Analyst high
$70.00
+493%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Profit margin
0.00%
Debt to equity
16.32
Analyst consensus
Strong Buy · 16 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 2.4% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashCash held in interest-bearing accounts and securities is 10.3% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 0.0% of assets, under the 49% limit.Pass
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Psychedelic Depression Drug Still Below Its True Worth
Imagine a patient stuck on antidepressants that stopped working years ago. COMPASS Pathways is running the late-stage trial that could deliver a new option using synthetic psilocybin. The shares sit at $12.35 against a $21 fair value, a 70 percent margin of safety, while fifteen analysts carry a strong-buy consensus and the same $21 median target.
The business is still pre-revenue with a forward P/E of minus 11.4 times, zero profit margin and return on equity of minus 68 percent. Those numbers are normal for a Phase III biotech, yet the ethical screen clears because the aim is treatment-resistant depression rather than any harmful product.
Risk sits in the usual clinical and regulatory hurdles plus the chance that peak earnings never arrive if the data disappoint. Currency moves and dilution from future raises add further pressure. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; its business and earnings are exposed to United Kingdom and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
PEERS
Related securities · others in CMPS's space worth a look
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
CMPS trades on Nasdaq (the company is based in United Kingdom). As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 87% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 134%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (15 analysts) rates it strong buy, with a mean price target of $22. Entered 2026-07-25 · Markup
JOURNAL
The dated journal · newest first, never edited
2026-07-25Markup$12.35+2.0%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 87% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 134%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (15 analysts) rates it strong buy, with a mean price target of $22.
2026-07-18Markup$12.11+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 87% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 134%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (15 analysts) rates it strong buy, with a mean price target of $22.
2026-07-03Markup$12.11+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (95). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$12.11Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with near-perfect ethical score (95). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
INSIDERS
The insider ledger · Form 4 filings, as filed
Most recent filings · CMPS
Date
Insider
Title
Type
Shares
Value
2026-03-26
LOXAM TERI
Chief Financial Officer
75,000
·
2026-03-26
NATH KABIR
Chief Executive Officer
175,000
·
2025-03-11
LOXAM TERI
Chief Financial Officer
25,000
·
2024-10-24
GOLDSMITH GEORGE JAY
Beneficial Owner of more than 10% of a Class of Security
776,565
$4,993,313
2024-10-24
MALIEVSKAIA EKATERINA
Beneficial Owner of more than 10% of a Class of Security
1,553,130
$9,986,626
2024-09-26
ATAI LIFE SCIENCES NV
Beneficial Owner of more than 10% of a Class of Security
